On the public citation graph
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
0 signed · 1537 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2016.4059openalex-snapshot
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
inferredcites →https://doi.org/10.1038/nature13954openalex-snapshot
PD-1 blockade induces responses by inhibiting adaptive immune resistance
inferredcites →https://doi.org/10.1038/nature14011openalex-snapshot
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
inferredcites →https://doi.org/10.1038/nrc3239openalex-snapshot
The blockade of immune checkpoints in cancer immunotherapy
inferredcites →https://doi.org/10.1038/sj.gt.3301885openalex-snapshot
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
inferredcites →https://doi.org/10.1056/nejmoa1200690openalex-snapshot
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
inferredcites →https://doi.org/10.1056/nejmoa1412082openalex-snapshot
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
inferredcites →https://doi.org/10.1056/nejmoa1503093openalex-snapshot
Pembrolizumab versus Ipilimumab in Advanced Melanoma
inferredcites →https://doi.org/10.1073/pnas.1300136110openalex-snapshot
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue
inferredcites →https://doi.org/10.1093/annonc/mdw379.04openalex-snapshot
Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
inferredcites →https://doi.org/10.1126/science.aaa8172openalex-snapshot
The future of immune checkpoint therapy
inferredcites →https://doi.org/10.1126/scitranslmed.3006504openalex-snapshot
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-1624openalex-snapshot
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
inferredcites →https://doi.org/10.1158/1078-0432.ccr-17-0681openalex-snapshot
Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade
inferredcites →https://doi.org/10.1158/2159-8290.cd-15-0563openalex-snapshot
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
inferredcites →https://doi.org/10.1158/2159-8290.cd-15-1545openalex-snapshot
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
inferredcites →https://doi.org/10.1188/16.onf.219-226openalex-snapshot
Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma
inferredcites →https://doi.org/10.1200/jco.2014.58.3377openalex-snapshot
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
inferredcites →https://doi.org/10.1200/jco.2014.59.4358openalex-snapshot
Immune Checkpoint Blockade in Cancer Therapy
inferredcites →https://doi.org/10.1200/jco.2015.33.15_suppl.3001openalex-snapshot
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
inferredcites →https://doi.org/10.1200/jco.2016.67.1529openalex-snapshot
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
inferredcites →https://doi.org/10.1200/jco.2016.67.2477openalex-snapshot
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.9509openalex-snapshot
Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.
inferredcites →https://doi.org/10.1245/s10434-009-0809-6openalex-snapshot
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
inferredcites →https://doi.org/10.1245/s10434-016-5286-0openalex-snapshot
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4652904openalex-extracted
A Dual-Functional Oncolytic Adenovirus Armed with Pd-L1 Inhibitor Potentiates its Antitumor Activity
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2019.9292openalex-snapshot
Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.7911openalex-snapshot
Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2026.23522openalex-snapshot
Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm066.pub2openalex-snapshot
Vaccines and Immunomodulators
inferred← citeshttps://doi.org/10.1002/9781119709268.rook144openalex-snapshot
Systemic Treatment of Melanoma
inferred← citeshttps://doi.org/10.1002/adbi.202000017openalex-snapshot
Immune Escape Mediated by Exosomal PD‐L1 in Cancer
inferred← citeshttps://doi.org/10.1002/adfm.201908788openalex-snapshot
Poly(cyclodextrin)‐Polydrug Nanocomplexes as Synthetic Oncolytic Virus for Locoregional Melanoma Chemoimmunotherapy
inferred← citeshttps://doi.org/10.1002/adfm.201908961openalex-snapshot
Inhibition of Immunosuppressive Tumors by Polymer‐Assisted Inductions of Immunogenic Cell Death and Multivalent PD‐L1 Crosslinking
inferred← citeshttps://doi.org/10.1002/adfm.202107540openalex-snapshot
Immune Cycle‐Based Strategies for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/adfm.202211698openalex-snapshot
Ferroptosis and Pyroptosis Co‐Activated Nanomodulator for “Cold” Tumor Immunotherapy and Lung Metastasis Inhibition
inferred← citeshttps://doi.org/10.1002/adhm.202202360openalex-snapshot
Rhythm Mild‐Temperature Photothermal Therapy Enhancing Immunogenic Cell Death Response in Oral Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1002/adhm.202401306openalex-snapshot
Nanomaterial‐Mediated Delivery of MLKL Plasmids Sensitizes Tumors to Immunotherapy and Reduces Metastases
inferred← citeshttps://doi.org/10.1002/adhm.202401851openalex-snapshot
Endoplasmic Reticulum Stress Nano‐Orchestrators for Precisely Regulated Immunogenic Cell Death as Potent Cancer Vaccines
inferred← citeshttps://doi.org/10.1002/adma.202007421openalex-snapshot
Materials for Improving Immune Cell Transfection
inferred← citeshttps://doi.org/10.1002/adma.202109354openalex-snapshot
The Development of Chiral Nanoparticles to Target NK Cells and CD8+ T Cells for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/adma.202210452openalex-snapshot
Biomaterial‐Based In Situ Cancer Vaccines
inferred← citeshttps://doi.org/10.1002/adma.75119openalex-snapshot
Nanozyme‐Assisted Engineered Oncolytic Adenovirus for Improving Intratumoral Immune Deficiency and Enhancing Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/adtp.202100144openalex-snapshot
Virus‐Mimic mRNA Vaccine for Cancer Treatment
inferred← citeshttps://doi.org/10.1002/adtp.202100151openalex-snapshot
Effective Combination Immunotherapy through Vessel Normalization Using a Cancer‐Targeting Antiangiogenic Peptide–Antibody Hybrid
inferred← citeshttps://doi.org/10.1002/adtp.202300445openalex-snapshot
Oncolytic Viruses in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/advs.201802281openalex-snapshot
Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis
inferred← citeshttps://doi.org/10.1002/advs.202002525openalex-snapshot
Nitric Oxide‐Driven Nanomotor for Deep Tissue Penetration and Multidrug Resistance Reversal in Cancer Therapy
inferred← citeshttps://doi.org/10.1002/advs.202101672openalex-snapshot
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
inferred← citeshttps://doi.org/10.1002/advs.202303907openalex-snapshot
Erythrocyte‐Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects
inferred← citeshttps://doi.org/10.1002/advs.202511605openalex-snapshot
rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma
inferred← citeshttps://doi.org/10.1002/cac2.12597openalex-snapshot
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response
inferred← citeshttps://doi.org/10.1002/cam4.1843openalex-snapshot
Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL‐24 enhances the antitumor effect of temozolomide against melanoma
inferred← citeshttps://doi.org/10.1002/cam4.2560openalex-snapshot
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
inferred← citeshttps://doi.org/10.1002/cam4.3438openalex-snapshot
Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma
inferred← citeshttps://doi.org/10.1002/cam4.4845openalex-snapshot
Oncolytic adenovirus H101 ameliorate the efficacy of anti‐PD ‐1 monotherapy in colorectal cancer
inferred← citeshttps://doi.org/10.1002/cbin.11559openalex-snapshot
A recombinant influenza virus with a CTLA4‐specific scFv inhibits tumor growth in a mouse model
inferred← citeshttps://doi.org/10.1002/ccr3.2182openalex-snapshot
Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient
inferred← citeshttps://doi.org/10.1002/cncr.31300openalex-snapshot
First person: Antoni Ribas, MD, PhD
inferred← citeshttps://doi.org/10.1002/cncr.35636openalex-snapshot
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases
inferred← citeshttps://doi.org/10.1002/cncr.70400openalex-snapshot
Updates on intratumoral therapies in melanoma
inferred← citeshttps://doi.org/10.1002/cpt.3379openalex-snapshot
Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab
inferred← citeshttps://doi.org/10.1002/cti2.1226openalex-snapshot
Therapeutic strategies to remodel immunologically cold tumors
inferred← citeshttps://doi.org/10.1002/ctm2.70503openalex-snapshot
Oncolytic viruses: Revolutionising the fight against tumours
inferred← citeshttps://doi.org/10.1002/gch2.202200094openalex-snapshot
Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic
inferred← citeshttps://doi.org/10.1002/hed.25930openalex-snapshot
Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions
inferred← citeshttps://doi.org/10.1002/ijc.32172openalex-snapshot
High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a)
inferred← citeshttps://doi.org/10.1002/ijc.33550openalex-snapshot
Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8 + PD ‐1− tumor‐infiltrating T cells in PD‐L1 ‐enriched tumor microenvironment
inferred← citeshttps://doi.org/10.1002/ijc.33703openalex-snapshot
Cytotoxic T lymphocyte‐associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells
inferred← citeshttps://doi.org/10.1002/ijc.34139openalex-snapshot
Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy
inferred← citeshttps://doi.org/10.1002/ijc.35103openalex-snapshot
Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition
inferred← citeshttps://doi.org/10.1002/iub.2558openalex-snapshot
PD ‐1/ PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
inferred← citeshttps://doi.org/10.1002/jbt.70675openalex-snapshot
Cross‐Cancer Perspectives on CD40 Agonist Therapy: Modulating the Tumor Immune Microenvironment
inferred← citeshttps://doi.org/10.1002/jhbp.944openalex-snapshot
Advances in immunotherapy for pancreatic ductal adenocarcinoma
inferred← citeshttps://doi.org/10.1002/jlb.3mir1017-400ropenalex-snapshot
Breaking self-tolerance during autoimmunity and cancer immunity: Myeloid cells and type I IFN response regulation
inferred← citeshttps://doi.org/10.1002/jlb.5bt0420-585rropenalex-snapshot
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
inferred← citeshttps://doi.org/10.1002/jlb.5mr0320-205ropenalex-snapshot
Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer
inferred← citeshttps://doi.org/10.1002/jmv.25501openalex-snapshot
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
inferred← citeshttps://doi.org/10.1002/jmv.26947openalex-snapshot
Current strategies of virotherapy in clinical trials for cancer treatment
inferred← citeshttps://doi.org/10.1002/jmv.28108openalex-snapshot
VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes
inferred← citeshttps://doi.org/10.1002/jmv.28729openalex-snapshot
Application of oncolytic virus in tumor therapy
inferred← citeshttps://doi.org/10.1002/jso.25601openalex-snapshot
Correlates of response and outcomes with talimogene laherperpvec
inferred← citeshttps://doi.org/10.1002/mco2.265openalex-snapshot
Understanding and targeting resistance mechanisms in cancer
inferred← citeshttps://doi.org/10.1002/mco2.343openalex-snapshot
Hot and cold tumors: Immunological features and the therapeutic strategies
inferred← citeshttps://doi.org/10.1002/mco2.70274openalex-snapshot
Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
inferred← citeshttps://doi.org/10.1002/mco2.70412openalex-snapshot
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
inferred← citeshttps://doi.org/10.1002/mco2.70771openalex-snapshot
Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies
inferred← citeshttps://doi.org/10.1002/mog2.21openalex-snapshot
Combining an adenovirus encoding human endostatin and PD‐1 blockade enhanced antitumor immune activity
inferred← citeshttps://doi.org/10.1002/mog2.49openalex-snapshot
cGAS‐STING signaling in cancer: Regulation and therapeutic targeting
inferred← citeshttps://doi.org/10.1002/smll.202103198openalex-snapshot
Mechanical Stimulation after Centrifuge‐Free Nano‐Electroporative Transfection Is Efficient and Maintains Long‐Term T Cell Functionalities
inferred← citeshttps://doi.org/10.1002/stem.3004openalex-snapshot
Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses
inferred← citeshttps://doi.org/10.1002/wnan.1632openalex-snapshot
Advances in engineering local drug delivery systems for cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/13905_2021_5openalex-snapshot
Perspective on the Immunotherapy of Gastric Cancer
inferred← citeshttps://doi.org/10.1007/16833_2022_121openalex-snapshot
Immunogenic Cell Death in Cancer
inferred← citeshttps://doi.org/10.1007/16833_2023_190openalex-snapshot
Oncolytic Virotherapy Against Breast Cancer
inferred← citeshttps://doi.org/10.1007/16833_2024_440openalex-snapshot
TIME Is Critical for Oncolytic Viral Therapies Against Solid Cancers
inferred← citeshttps://doi.org/10.1007/978-1-4614-7147-9_36openalex-snapshot
Melanoma Immunology and Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-1-4614-7147-9_39openalex-snapshot
Viral-Based Therapies in Melanoma
inferred← citeshttps://doi.org/10.1007/978-1-4614-7322-0_36-1openalex-snapshot
Introduction to Melanoma Immunology
inferred← citeshttps://doi.org/10.1007/978-1-4614-7322-0_36-2openalex-snapshot
Melanoma Immunology and Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-1-4614-7322-0_39-1openalex-snapshot
Viral-Based Therapies in Melanoma
inferred← citeshttps://doi.org/10.1007/978-1-4939-0428-0_5openalex-snapshot
Engineering HSV-1 Vectors for Gene Therapy
inferred← citeshttps://doi.org/10.1007/978-1-4939-9794-7_21openalex-snapshot
Mathematical Modeling of Oncolytic Virotherapy
inferred← citeshttps://doi.org/10.1007/978-1-4939-9814-2_4openalex-snapshot
Engineering HSV-1 Vectors for Gene Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-02505-2_2openalex-snapshot
Immunotherapy for Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-05070-2_59openalex-snapshot
Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-21477-7_3openalex-snapshot
Current Challenges and Applications of Oncolytic Viruses in Overcoming the Development of Resistance to Therapies in Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-23765-3_6openalex-snapshot
The Era of Checkpoint Inhibition: Lessons Learned from Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-26887-9_15openalex-snapshot
Treatment: Future Directions
inferred← citeshttps://doi.org/10.1007/978-3-030-28891-4_19openalex-snapshot
Novel Techniques and the Future of HIPEC (Immunotherapy, Viral Therapy)
inferred← citeshttps://doi.org/10.1007/978-3-030-28891-4_2openalex-snapshot
Novel Biological Therapies with Direct Application to the Peritoneal Cavity
inferred← citeshttps://doi.org/10.1007/978-3-030-28891-4_5openalex-snapshot
Regional Gene Therapy for Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-41008-7_3openalex-snapshot
Immunotherapy for Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-43085-6_5openalex-snapshot
Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma
inferred← citeshttps://doi.org/10.1007/978-3-030-51192-0_115-1openalex-snapshot
Intratumoral Delivery of Novel Therapies
inferred← citeshttps://doi.org/10.1007/978-3-030-55617-4_4openalex-snapshot
Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses
inferred← citeshttps://doi.org/10.1007/978-3-030-64009-5_13openalex-snapshot
Talimogene Laherparepvec (T-VEC)
inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_3openalex-snapshot
Immunotherapy for Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_205-2openalex-snapshot
Cancer Immunotherapy Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-030-93084-4_36openalex-snapshot
The Role of Surgery in Managing Primary and Metastatic Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-96376-7_3openalex-snapshot
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity
inferred← citeshttps://doi.org/10.1007/978-3-031-29750-2_17openalex-snapshot
Immunotherapy for Meningiomas
inferred← citeshttps://doi.org/10.1007/978-3-031-49762-9_115openalex-snapshot
Intratumoral Delivery of Novel Therapies
inferred← citeshttps://doi.org/10.1007/978-3-031-56968-5_33openalex-snapshot
Immunotherapy for Neuroendocrine Neoplasms
inferred← citeshttps://doi.org/10.1007/978-3-031-59128-0_5openalex-snapshot
Treatment for Regionally Advanced and In-transit Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-031-84539-0_22openalex-snapshot
Intratumoral Drug Administration: More Potential in Head and Neck Cancer?
inferred← citeshttps://doi.org/10.1007/978-3-031-97242-3_6openalex-snapshot
Immunotherapy in Glioblastoma
inferred← citeshttps://doi.org/10.1007/978-3-032-00767-4_205openalex-snapshot
Cancer Immunotherapy Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-319-46029-1_59-1openalex-snapshot
Novel Immunotherapies and Novel Combinations of Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-319-56637-5_51-1openalex-snapshot
Pharmacodynamic Evaluation: Gene Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-68864-0_51openalex-snapshot
Pharmacodynamic Evaluation: Gene Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-78310-9_35openalex-snapshot
Current Immunotherapy of Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_207-1openalex-snapshot
Intraläsionale Therapie (Interferon, onkolytische Viren etc.)
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_54-1openalex-snapshot
Checkpoint-Inhibitoren
inferred← citeshttps://doi.org/10.1007/978-3-662-62808-9_13openalex-snapshot
Perspektiven der medikamentösen Tumortherapie
inferred← citeshttps://doi.org/10.1007/978-981-15-8640-8_10openalex-snapshot
Control Strategies for Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-981-99-7141-1_12openalex-snapshot
Vaccines and Oncolytic Virus for the Treatment of Lung Cancer
inferred← citeshttps://doi.org/10.1007/s00018-021-03842-6openalex-snapshot
Nanoparticle-based approaches to target the lymphatic system for antitumor treatment
inferred← citeshttps://doi.org/10.1007/s00018-022-04219-zopenalex-snapshot
Type I interferon-mediated tumor immunity and its role in immunotherapy
inferred← citeshttps://doi.org/10.1007/s00105-018-4124-7openalex-snapshot
Aktuelle Aspekte in der Prognose des fortgeschrittenen Melanoms
inferred← citeshttps://doi.org/10.1007/s00259-022-05968-6openalex-snapshot
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/s00262-018-2244-7openalex-snapshot
Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy
inferred← citeshttps://doi.org/10.1007/s00262-019-02377-xopenalex-snapshot
Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone
inferred← citeshttps://doi.org/10.1007/s00262-020-02487-xopenalex-snapshot
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
inferred← citeshttps://doi.org/10.1007/s00262-020-02495-xopenalex-snapshot
Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
inferred← citeshttps://doi.org/10.1007/s00262-020-02509-8openalex-snapshot
Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study
inferred← citeshttps://doi.org/10.1007/s00262-020-02534-7openalex-snapshot
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
inferred← citeshttps://doi.org/10.1007/s00262-020-02839-7openalex-snapshot
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model
inferred← citeshttps://doi.org/10.1007/s00262-021-02860-4openalex-snapshot
IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity
inferred← citeshttps://doi.org/10.1007/s00262-021-03084-2openalex-snapshot
Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing
inferred← citeshttps://doi.org/10.1007/s00262-021-03088-yopenalex-snapshot
Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma
inferred← citeshttps://doi.org/10.1007/s00262-021-03122-zopenalex-snapshot
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma
inferred← citeshttps://doi.org/10.1007/s00262-022-03314-1openalex-snapshot
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
inferred← citeshttps://doi.org/10.1007/s00262-024-03825-zopenalex-snapshot
Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00262-026-04458-0openalex-snapshot
Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy
inferred← citeshttps://doi.org/10.1007/s00281-018-0692-yopenalex-snapshot
Acquired resistance to cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/s00281-022-00960-6openalex-snapshot
Local anesthetics and immunotherapy: a novel combination to fight cancer
inferred← citeshttps://doi.org/10.1007/s00335-018-9786-zopenalex-snapshot
Perspective: cancer vaccines in the era of immune checkpoint blockade
inferred← citeshttps://doi.org/10.1007/s00384-024-04654-3openalex-snapshot
PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review
inferred← citeshttps://doi.org/10.1007/s00428-018-2506-yopenalex-snapshot
Rational combination of cancer immunotherapy in melanoma
inferred← citeshttps://doi.org/10.1007/s00428-019-02538-4openalex-snapshot
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
inferred← citeshttps://doi.org/10.1007/s00432-022-03931-4openalex-snapshot
Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report
inferred← citeshttps://doi.org/10.1007/s00432-022-04399-yopenalex-snapshot
Cancer-associated inflammation: pathophysiology and clinical significance
inferred← citeshttps://doi.org/10.1007/s00432-022-04509-wopenalex-snapshot
IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways
inferred← citeshttps://doi.org/10.1007/s00432-023-05501-8openalex-snapshot
Intratumoral delivery of a Tim-3 antibody-encoding oncolytic adenovirus engages an effective antitumor immune response in liver cancer
inferred← citeshttps://doi.org/10.1007/s00705-023-05754-1openalex-snapshot
An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer
inferred← citeshttps://doi.org/10.1007/s00761-019-0582-5openalex-snapshot
Neue Therapieansätze beim metastasierten Nierenzellkarzinom
inferred← citeshttps://doi.org/10.1007/s10147-020-01760-4openalex-snapshot
Oncolytic virus combined with traditional treatment versus traditional treatment alone in patients with cancer: a meta-analysis
inferred← citeshttps://doi.org/10.1007/s10238-024-01376-2openalex-snapshot
Cancer biotherapy: review and prospect
inferred← citeshttps://doi.org/10.1007/s10238-024-01443-8openalex-snapshot
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/s10238-026-02056-zopenalex-snapshot
Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges
inferred← citeshttps://doi.org/10.1007/s10495-020-01595-4openalex-snapshot
Potent antitumor activity of oncolytic adenovirus expressing C/EBPβ against hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s10529-021-03173-3openalex-snapshot
The application of oncolytic viruses in cancer therapy
inferred← citeshttps://doi.org/10.1007/s10555-019-09819-zopenalex-snapshot
Immunotherapies for pediatric cancer: current landscape and future perspectives
inferred← citeshttps://doi.org/10.1007/s10585-018-9890-1openalex-snapshot
Regional therapies for locoregionally advanced and unresectable melanoma
inferred← citeshttps://doi.org/10.1007/s10585-021-10100-3openalex-snapshot
In-transit metastatic cutaneous melanoma: current management and future directions
inferred← citeshttps://doi.org/10.1007/s10620-020-06183-9openalex-snapshot
Dilemma and Challenge of Immunotherapy for Pancreatic Cancer
inferred← citeshttps://doi.org/10.1007/s10735-025-10570-9openalex-snapshot
Role of indoleamine 2,3-Dioxygenase 1 in modulating the malignant biological behavior of cervical cancer cells through the Tryptophan-Kynurenine pathway
inferred← citeshttps://doi.org/10.1007/s10967-024-09723-zopenalex-snapshot
89Zr PET imaging guided validation of the medicinal potentiality of UiO-66 based nano drug delivery system
inferred← citeshttps://doi.org/10.1007/s11060-020-03684-5openalex-snapshot
Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies
inferred← citeshttps://doi.org/10.1007/s11307-021-01652-7openalex-snapshot
ImmunoPET: harnessing antibodies for imaging immune cells
inferred← citeshttps://doi.org/10.1007/s11427-020-1768-yopenalex-snapshot
Current status and future perspectives of immunotherapy in bladder cancer treatment
inferred← citeshttps://doi.org/10.1007/s11538-026-01746-9openalex-snapshot
Allee Effect and Oncolytic Virotherapy: Different Therapeutic Outcomes for Different Tumour Growth
inferred← citeshttps://doi.org/10.1007/s11684-020-0746-0openalex-snapshot
Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system
inferred← citeshttps://doi.org/10.1007/s11684-020-0750-4openalex-snapshot
Development of oncolytic virotherapy: from genetic modification to combination therapy
inferred← citeshttps://doi.org/10.1007/s11684-023-1015-9openalex-snapshot
Heterogeneity of the tumor immune microenvironment and clinical interventions
inferred← citeshttps://doi.org/10.1007/s11684-023-1048-0openalex-snapshot
Immune landscape and response to oncolytic virus-based immunotherapy
inferred← citeshttps://doi.org/10.1007/s11864-023-01143-7openalex-snapshot
Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities
inferred← citeshttps://doi.org/10.1007/s11864-024-01211-6openalex-snapshot
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas
inferred← citeshttps://doi.org/10.1007/s11864-025-01377-7openalex-snapshot
Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment
inferred← citeshttps://doi.org/10.1007/s11910-025-01428-4openalex-snapshot
Virus Against Cancer: Paradigm-Shifting Biological Concepts
inferred← citeshttps://doi.org/10.1007/s11912-020-0894-zopenalex-snapshot
Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
inferred← citeshttps://doi.org/10.1007/s11912-022-01341-wopenalex-snapshot
Oncolytic Viruses and Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1007/s12010-024-05130-yopenalex-snapshot
Identification and Validation of Molecular Features of the Anoikis Gene-Related Hub Genes in Nasopharyngeal Carcinoma
inferred← citeshttps://doi.org/10.1007/s12015-021-10207-wopenalex-snapshot
Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses
inferred← citeshttps://doi.org/10.1007/s12032-022-01842-5openalex-snapshot
Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies
inferred← citeshttps://doi.org/10.1007/s12032-023-02233-0openalex-snapshot
Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment
inferred← citeshttps://doi.org/10.1007/s12094-022-02830-xopenalex-snapshot
Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical
inferred← citeshttps://doi.org/10.1007/s12250-020-00339-7openalex-snapshot
Visualization of the Oncolytic Alphavirus M1 Life Cycle in Cancer Cells
inferred← citeshttps://doi.org/10.1007/s12254-020-00640-xopenalex-snapshot
The future of combination therapies in advanced melanoma
inferred← citeshttps://doi.org/10.1007/s12274-021-4031-6openalex-snapshot
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/s12325-020-01590-wopenalex-snapshot
A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
inferred← citeshttps://doi.org/10.1007/s12609-023-00492-4openalex-snapshot
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
inferred← citeshttps://doi.org/10.1007/s12672-023-00769-1openalex-snapshot
Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review
inferred← citeshttps://doi.org/10.1007/s13337-026-00964-yopenalex-snapshot
Oncolytic viruses in cancer therapy development: the evolution of cell culture models in preclinical research
inferred← citeshttps://doi.org/10.1007/s13402-020-00534-4openalex-snapshot
HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers
inferred← citeshttps://doi.org/10.1007/s13555-021-00583-zopenalex-snapshot
Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review
inferred← citeshttps://doi.org/10.1007/s40136-022-00402-9openalex-snapshot
Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/s40257-020-00554-8openalex-snapshot
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions
inferred← citeshttps://doi.org/10.1007/s40257-023-00762-yopenalex-snapshot
Treatment of Recurrent Melanoma Following Adjuvant Therapy
inferred← citeshttps://doi.org/10.1007/s40257-023-00841-0openalex-snapshot
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
inferred← citeshttps://doi.org/10.1007/s40259-019-00367-0openalex-snapshot
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1007/s40265-018-0945-zopenalex-snapshot
Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
inferred← citeshttps://doi.org/10.1007/s40265-018-0970-yopenalex-snapshot
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/s40265-020-01270-7openalex-snapshot
Mechanisms of Resistance to PD-1 Checkpoint Blockade
inferred← citeshttps://doi.org/10.1007/s40291-023-00689-4openalex-snapshot
Personalizing Oncolytic Immunovirotherapy Approaches
inferred← citeshttps://doi.org/10.1007/s42452-026-08439-xopenalex-snapshot
Expanding horizons of immunotherapy: from oncology to multisystemic applications
inferred← citeshttps://doi.org/10.1007/s44337-025-00328-3openalex-snapshot
Exploring the potential of oncolytic viral vectors in targeted cancer therapy: advances, challenges and future directions
inferred← citeshttps://doi.org/10.1007/s44466-026-00055-zopenalex-snapshot
When oncolytic viruses get on CAR: a synergic approach for solid tumor immunotherapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-814515-9.00091-6openalex-snapshot
Virus-Based Cancer Therapeutics
showing the first 200 of 1512 · page through all 1512
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.